- Home
- CZNC vs STRO Comparison
CZNC vs STRO Comparison
Compare CZNC & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | STRO |
|---|---|---|
| Founded | 1864 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.9M | 94.9M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CZNC | STRO |
|---|---|---|
| Price | $21.98 | $9.03 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 7 |
| Target Price | ★ $22.00 | $19.67 |
| AVG Volume (30 Days) | 61.6K | ★ 110.8K |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | ★ 5.10% | N/A |
| EPS Growth | ★ 22.09 | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $109,632,000.00 | $105,646,000.00 |
| Revenue This Year | $5.72 | $62.61 |
| Revenue Next Year | $7.18 | N/A |
| P/E Ratio | $12.54 | ★ N/A |
| Revenue Growth | ★ 7.59 | N/A |
| 52 Week Low | $17.85 | $5.23 |
| 52 Week High | $22.68 | $21.90 |
Technical Indicators
Market Signals| Indicator | CZNC | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 74.31 | 77.00 |
| Support Level | $20.98 | $9.53 |
| Resistance Level | $20.67 | $10.10 |
| Average True Range (ATR) | 0.43 | 0.78 |
| MACD | 0.17 | 0.36 |
| Stochastic Oscillator | 83.37 | 89.12 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.